---
title: "CHENGDA PHARMA: Expected net loss of RMB 21 million to RMB 29 million in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225181800.md"
description: "CHENGDA PHARMA expects a net profit loss of 21 million to 29 million yuan in 2024, compared to a profit of 90.98 million yuan in the same period last year. After deducting non-recurring gains and losses, the net profit loss is expected to be 50 million to 60 million yuan. The performance change is mainly due to a year-on-year decline in operating revenue of 16%-27%, with sales revenue from the raw material drug business decreasing by approximately 33%. The company is increasing its investment in research and development, with R&D expenses expected to be between 90 million and 98 million yuan, an increase of more than 66 million yuan compared to the previous year, along with additional depreciation expenses of approximately 8.33 million yuan and the impact of non-recurring gains and losses of about 30 million yuan"
datetime: "2025-01-16T10:18:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225181800.md)
  - [en](https://longbridge.com/en/news/225181800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225181800.md)
---

# CHENGDA PHARMA: Expected net loss of RMB 21 million to RMB 29 million in 2024

CHENGDA PHARMA announced that it expects a net loss attributable to shareholders of the listed company of 21 million to 29 million yuan from January 1, 2024, to December 31, 2024, compared to a profit of 90.98 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is expected to be 50 million to 60 million yuan, compared to a profit of 53.82 million yuan in the same period last year. The main reason for the performance change is a year-on-year decline in operating income of approximately 16% to 27%, with sales revenue from the raw material drug business decreasing by about 33% year-on-year; the company continues to increase R&D investment, with R&D expenses of approximately 90 million to 98 million yuan, an increase of about 66 million yuan compared to the previous year; new depreciation expenses of approximately 8.33 million yuan; the impact of non-recurring gains and losses on net profit is approximately 30 million yuan

### Related Stocks

- [301201.CN](https://longbridge.com/en/quote/301201.CN.md)

## Related News & Research

- [Ray Dalio Says US Is in Decline: 'Threats No Longer Work' in a World Where Order Breaks Down](https://longbridge.com/en/news/294556219.md)
- [Is Citadel's Surprise July Rate Hike Call Viable? Jim Bianco Says 38% Market Odds Mean It's 'Not That Far'](https://longbridge.com/en/news/294029822.md)
- [Orion Diversified Holding buys 0.61% working interest in North Dakota Wiley Glenburn Unit](https://longbridge.com/en/news/293955142.md)
- [Muyuan Foods says Stock Exchange disciplinary statement on Redco does not affect director Chow Ming Sang’s duties](https://longbridge.com/en/news/294188255.md)
- [Thyssenkrupp Nucera hands over skid-mounted chlor-alkali plant to Chlorum Solutions in Brazil](https://longbridge.com/en/news/294180764.md)